Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

New strategy identified for overcoming resistance to KRAS-targeted cancer therapies (opens in a new tab)

news-medical.net · 2026-10-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 4 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe work was a preclinical study published in Cancer Research and led by Vishnu Kumarasamy, Agnieszka Witkiewicz, and Erik Knudsen.View evidenceHide evidence

Why this verdict

The profile supports that the work is preclinical, involving in vitro resistant models and animal xenografts. However, the supplied abstract-depth paper profile does not verify the journal publication venue or the named study leaders/authors, so the full claim cannot be confirmed at this evidence depth.

1

Study evidence

Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.

“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
2

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Claim 2 of 6Not coveredCombination approaches produced more durable tumor control in laboratory and animal models than KRAS inhibition alone.View evidenceHide evidence

Why this verdict

The profile supports durable effects from combination approaches: CDK2 cotargeting produced a more durable cytostatic response in vitro, and concurrent KRAS inhibition with CDK4/6 or CDK2 yielded durable tumor control in xenograft models. However, at abstract depth the profile does not provide quantitative comparative data or explicitly verify the story's full comparator claim that combination approaches were more durable than KRAS inhibition alone across both laboratory and animal models.

1

Study evidence

Cotargeting CDK2 impaired DNA replication in resistant models.

“cotargeting CDK2 exerted a broader effect by impairing DNA replication, inducing G2 arrest, preventing mitotic entry”
2

Study evidence

Concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.

“concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.”
Claim 3 of 6SupportedRoswell Park Comprehensive Cancer Center researchers identified a promising strategy for overcoming resistance to KRAS-targeted cancer therapies.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the researchers identified a preclinical cell-cycle cotargeting strategy: resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite KRAS suppression, and functional screens plus xenograft studies support CDK4/6 or CDK2 cotargeting as a way to restore sensitivity and achieve durable tumor control. The headline-style phrasing is acceptable because it is hedged as a 'promising strategy,' though the evidence is preclinical rather than clinical.

1

Study evidence

Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.

“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
2

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Claim 4 of 6SupportedEven when RAS signaling was blocked, cancer cells could maintain proliferation by activating alternative pathways, and persistent cell-cycle activity emerged as a common feature of resistant tumors.View evidenceHide evidence

Why this verdict

The abstract-level profile states that, despite effective suppression of mutant KRAS signaling, resistant cells sustained cell-cycle progression and engaged distinct orthogonal mitogenic pathways in a context-dependent manner to bypass KRAS inhibition. The story's wording accurately captures the association between blocked RAS signaling, alternative pathway engagement, and persistent cell-cycle activity, although it simplifies the context-dependent nature of the bypass pathways.

1

Study evidence

Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.

“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
Claim 5 of 6SupportedBlocking the cell-cycle regulators CDK4/6 or CDK2 restored sensitivity to KRAS- and RAS-targeted therapies.View evidenceHide evidence

Why this verdict

The profile reports combinatorial drug screens and genome-wide CRISPR–Cas9 screens showing that perturbing CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors in resistant models. Because these were experimental preclinical perturbations, the causal wording is supported within that model-system context.

1

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
2

Study evidence

Genome-wide CRISPR–Cas9 loss-of-function screens in resistant models identified CDK4/6 and CDK2 as genetic perturbations that restore sensitivity to KRAS/RAS inhibitors.

“... and genome-wide CRISPR–Cas9 screens showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Claim 6 of 6SupportedThe findings may help guide future clinical strategies to extend the effectiveness of KRAS-targeted medicines and delay disease progression.View evidenceHide evidence

Why this verdict

The story frames this as a hedged future clinical implication rather than a demonstrated clinical outcome. The abstract-level profile supports a preclinical rationale for cell-cycle cotargeting to overcome acquired KRAS/RAS-inhibitor resistance. The claim should be read with the limitation that clinical efficacy, progression delay, and safety/tolerability were not tested in the profiled evidence.

1

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
2

Study evidence

Genome-wide CRISPR–Cas9 loss-of-function screens in resistant models identified CDK4/6 and CDK2 as genetic perturbations that restore sensitivity to KRAS/RAS inhibitors.

“... and genome-wide CRISPR–Cas9 screens showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • CDK4/6 and CDK2 cotargeting have different mechanistic/phenotypic effects: CDK4/6 cotargeting induces G1 arrest and E2F suppression, whereas CDK2 cotargeting impairs DNA replication, induces G2 arrest, prevents mitotic entry, and delays outgrowth after withdrawal.

    The story mentions CDK4/6 and CDK2 as targets and refers broadly to durable control, but it does not report the mechanistic distinction between the two cotargeting strategies.

    From in vitro; in vitro

  • The abstract mentions pan-RAS-ON inhibition with RMC-6236 and acquired resistance in which proliferation becomes uncoupled from RAS signaling.

    The story discusses RAS-targeted therapies and resistance generally but does not include the specific RMC-6236/pan-RAS-ON inhibitor element from the abstract-level profile.

    From In vitro molecular profiling of resistant models

6 things the story did carry across
  • Resistant KRAS/RAS-inhibitor cancer models sustain cell-cycle progression despite effective mutant KRAS/RAS pathway suppression.
  • Resistance involves distinct, context-dependent orthogonal mitogenic bypass pathways.
  • Combinatorial drug screens and genome-wide CRISPR–Cas9 screens identified CDK4/6 and CDK2 as cell-cycle nodes whose perturbation restores KRAS/RAS-inhibitor sensitivity.
  • Concurrent KRAS inhibition with either CDK4/6 or CDK2 inhibition yielded durable tumor control in xenografts derived from acquired-resistance models.
  • The evidence is preclinical, based on in vitro resistant models and mouse xenograft models rather than human clinical outcome data.
  • Clinical translatability, safety/tolerability of combinations, and actual delay of disease progression in patients were not addressed by the profiled evidence.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroCombinatorial functional screens (drug combination screens and genome-wide CRISPR–Cas9 screens) identify cell-cycle nodes (CDK4/6 and CDK2) whose perturbation restores sensitivity to KRAS/RAS inhibitors in resistant models.Combinatorial drug screening; genome-wide CRISPR–Cas9 loss-of-function screeningExpand

In plain English

Combinatorial drug screens and genome-wide CRISPR–Cas9 loss-of-function screens performed in resistant in vitro cancer models identified cyclin-dependent kinases CDK4/6 and CDK2 as cell-cycle nodes whose perturbation restored sensitivity to KRAS- or pan-RAS inhibitors.

Key findings

  • Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.
“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroResistant KRAS/ RAS-inhibitor cancer models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling, via context-dependent engagement of orthogonal mitogenic pathways.In vitro molecular profiling of resistant modelsExpand

In plain English

Transcriptomic and proteomic profiling of KRAS/RAS-inhibitor–resistant cancer models shows that, despite effective suppression of mutant KRAS signaling, resistant cells maintain cell-cycle progression by engaging distinct, context-dependent mitogenic bypass pathways; broad pan‑RAS-ON inhibition (RMC-6236) can suppress these pathways but cells can acquire resistance in which proliferation becomes uncoupled from RAS signaling.

Key findings

  • Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.
  • Distinct orthogonal mitogenic pathways are engaged in a context-dependent manner to bypass KRAS inhibition.
“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vitroCombinatorial functional screens (drug combination screens and genome-wide CRISPR–Cas9 screens) identify cell-cycle nodes (CDK4/6 and CDK2) whose perturbation restores sensitivity to KRAS/RAS inhibitors in resistant models.Genome-wide CRISPR–Cas9 loss-of-function screenExpand

In plain English

The paper reports genome-wide CRISPR–Cas9 loss-of-function screens performed in KRAS/RAS-inhibitor–resistant models that identified cell-cycle regulatory nodes, specifically CDK4/6 and CDK2, whose genetic perturbation restored sensitivity to KRAS/RAS inhibitors.

Key findings

  • Genome-wide CRISPR–Cas9 loss-of-function screens in resistant models identified CDK4/6 and CDK2 as genetic perturbations that restore sensitivity to KRAS/RAS inhibitors.
“... and genome-wide CRISPR–Cas9 screens showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
What this piece can’t prove
  • All information is drawn from the paper abstract; methodological and numerical details of the genome-wide CRISPR–Cas9 screens are not provided there.

2 further details could not be confirmed from the summary.

4in vitroMechanistic/phenotypic profiling distinguishes CDK4/6 versus CDK2 cotargeting effects on cell-cycle state and durability of cytostasis (e.g., G1 arrest/E2F suppression vs impaired DNA replication, G2 arrest, mitotic entry prevention, delayed outgrowth after withdrawal).Expand

In plain English

In vitro mechanistic profiling reported that cotargeting KRAS/RAS inhibitors with CDK4/6 inhibition induced G1 cell-cycle arrest and suppressed E2F-regulated protein expression across resistant models.

Key findings

  • Cotargeting CDK4/6 with KRAS/RAS inhibitors produced G1 arrest and suppression of E2F-regulated proteins across resistant models.
“Cotargeting CDK4/6 induced G1 arrest and suppressed E2F-regulated proteins across all resistant models.”
What this piece can’t prove
  • Methods are described only at a high level; specific assays, reagents, and time courses are not detailed.

3 further details could not be confirmed from the summary.

5in vitroMechanistic/phenotypic profiling distinguishes CDK4/6 versus CDK2 cotargeting effects on cell-cycle state and durability of cytostasis (e.g., G1 arrest/E2F suppression vs impaired DNA replication, G2 arrest, mitotic entry prevention, delayed outgrowth after withdrawal).Expand

In plain English

In models with acquired resistance to KRAS/RAS inhibitors, cotargeting CDK2 (concurrent with KRAS/RAS inhibition) impaired DNA replication, induced G2 arrest and prevented mitotic entry, and produced a more durable cytostatic response that delayed cellular outgrowth after drug withdrawal (as reported in the abstract).

Key findings

  • Cotargeting CDK2 impaired DNA replication in resistant models.
  • Cotargeting CDK2 induced G2 arrest and prevented mitotic entry.
“cotargeting CDK2 exerted a broader effect by impairing DNA replication, inducing G2 arrest, preventing mitotic entry”
What this piece can’t prove
  • The abstract does not specify which cell lines or resistant models were used for the reported in vitro mechanistic profiling.

2 further details could not be confirmed from the summary.

6in vivo animalIn vivo validation: concurrent inhibition of KRAS with either CDK4/6 or CDK2 yields durable tumor control in xenografts derived from acquired-resistance models.in vivo xenograft efficacy studyExpand

In plain English

In mouse xenograft efficacy studies using tumors derived from models with acquired resistance to KRAS/RAS inhibitors, concurrent pharmacologic inhibition of KRAS together with either CDK4/6 or CDK2 produced durable tumor control in vivo, indicating that cotargeting cell-cycle nodes can overcome acquired resistance in these preclinical models.

Key findings

  • Concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.
“concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Abstract 4434: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors

Cancer Research · 2025 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.